|
Market Closed -
Nasdaq
23:00:00 28/10/2026 +03
|
Pre-market 16:29:10 | |||
| 142.14 USD | +0.72% |
|
143.63 | +1.05% |
| 10-23 | UK approves J&J's oral psoriasis pill | RE |
| 10-12 | UBS Initiates Coverage on Protagonist Therapeutics With Buy Rating, $184 Price Target | MT |
| Market Cap | 9.2B 8.25B 7.63B 6.91B 12.91B 876B 13.07B 91.22B 36.33B 458B 34.52B 33.79B 1,455B | P/E 2026 * |
30.6x | P/E 2027 * | -469x |
|---|---|---|---|---|---|
| Enterprise Value | 8.67B 7.78B 7.19B 6.51B 12.17B 826B 12.32B 85.99B 34.25B 432B 32.54B 31.85B 1,372B | EV / Sales 2026 * |
15.8x | EV / Sales 2027 * | 40.4x |
| Free-Float |
97.68% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| PTGX | Delayed | |
CBOE
| PTGX | Real-time | |
|
Tradegate
| PGF | Real-time |
Last Transcript: Protagonist Therapeutics, Inc.
| 1 day | +0.72% | ||
| 1 week | +2.94% | ||
| Current month | +0.89% | ||
| 1 month | -0.21% | ||
| 3 months | +3.87% | ||
| 6 months | +40.44% | ||
| Current year | +62.74% |
| 1 week | 135 |  | 143.26 |
| 1 month | 126.39 | | 152.18 |
| Current year | 77 | | 160.81 |
| 1 year | 75.44 | | 160.81 |
| 3 years | 13.76 | | 160.81 |
| 5 years | 6.91 | | 160.81 |
| 10 years | 4.47 | | 160.81 |
| Manager | Title | Age | Since |
|---|---|---|---|
Dinesh Patel
CEO | Chief Executive Officer | 69 | 01/12/2008 |
Asif Ali
DFI | Director of Finance/CFO | 52 | 18/04/2022 |
Venkat Thalladi
CTO | Chief Tech/Sci/R&D Officer | - | 01/04/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Dinesh Patel
BRD | Director/Board Member | 69 | 01/12/2008 |
Harold Selick
CHM | Chairman | 71 | 19/03/2014 |
William Waddill
BRD | Director/Board Member | 69 | 01/07/2016 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/30/26 A | Exercice | Chief Financial Officer | 175,887 | 0.2718% | ||
| 9/10/26 A | Exercice | Chief Executive Officer | 21,834 | 0.0337% | ||
| 9/3/26 A | Don | Chief Executive Officer | -510 | 0.0008% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.72% | +2.94% | +81.05% | +909.52% | 9.2B | |
| +0.65% | -3.36% | +36.98% | +60.50% | 64.14B | |
| +1.76% | +3.40% | +13.03% | +85.19% | 55.53B | |
| +1.57% | +1.88% | +13.15% | +105.46% | 53.03B | |
| +2.76% | +0.87% | +27.92% | +55.07% | 45.99B | |
| +2.00% | -3.39% | +17.83% | +119.04% | 42.45B | |
| +1.34% | -2.86% | +224.43% | +914.08% | 40.45B | |
| +0.64% | -3.95% | +11.15% | +45.57% | 32.25B | |
| -1.75% | +42.46% | +103.39% | +89.90% | 34.47B | |
| -2.72% | -0.44% | +23.18% | -10.77% | 24.23B | |
| Average | +0.69% | +3.97% | +55.21% | +237.36% | 40.17B | |
| Weighted average by Cap. | +0.96% | +3.47% | +50.14% | +177.82% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 549M 493M 455M 412M 771M 52.29B 780M 5.45B 2.17B 27.36B 2.06B 2.02B 86.86B | 215M 193M 179M 162M 302M 20.52B 306M 2.14B 851M 10.74B 809M 792M 34.09B |
| Net income | 326M 293M 271M 245M 458M 31.07B 463M 3.24B 1.29B 16.26B 1.22B 1.2B 51.61B | -18.36M -16.47M -15.23M -13.79M -25.76M -1.75B -26.07M -182M -72.51M -915M -68.88M -67.43M -2.9B |
| Net Debt | -527M -473M -437M -396M -740M -50.18B -748M -5.23B -2.08B -26.26B -1.98B -1.94B -83.37B | -494M -443M -410M -371M -694M -47.07B -702M -4.9B -1.95B -24.63B -1.85B -1.82B -78.19B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/10/26 | $142.14 | +0.72% | 318,458 |
| 27/10/26 | $141.12 | +0.57% | 865,925 |
| 26/10/26 | $140.32 | +1.37% | 823,277 |
| 23/10/26 | $138.43 | -0.79% | 409,356 |
| 22/10/26 | $139.53 | +1.05% | 404,387 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PTGX Stock
Select your edition
All financial news and data tailored to specific country editions
